Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Effect of atrioventricular optimization on circulating N-terminal pro brain natriuretic peptide following cardiac resynchronization therapy.

Shanmugam N, Campos AG, Prada-Delgado O, Bizrah M, Valencia O, Jones S, Collinson P, Anderson L.

Eur J Heart Fail. 2013 May;15(5):534-42. doi: 10.1093/eurjhf/hft012. Epub 2013 Feb 6.

2.

Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure.

Yu CM, Fung JW, Zhang Q, Chan CK, Chan I, Chan YS, Kong SL, Sanderson JE, Lam CW.

J Card Fail. 2005 Jun;11(5 Suppl):S42-6.

PMID:
15948100
3.

Clinical, echocardiographic, and neurohormonal response to cardiac resynchronization therapy: are they interchangeable?

Hoogslag GE, Höke U, Thijssen J, Auger D, Marsan NA, Wolterbeek R, Holman ER, Schalij MJ, Bax JJ, Verwey HF, Delgado V.

Pacing Clin Electrophysiol. 2013 Nov;36(11):1391-401. doi: 10.1111/pace.12214. Epub 2013 Jul 4.

PMID:
23826659
4.

N-terminal pro-brain natriuretic peptide testing in the emergency department: beneficial effects on hospitalization, costs, and outcome.

Rutten JH, Steyerberg EW, Boomsma F, van Saase JL, Deckers JW, Hoogsteden HC, Lindemans J, van den Meiracker AH.

Am Heart J. 2008 Jul;156(1):71-7. doi: 10.1016/j.ahj.2008.02.021. Epub 2008 May 27.

PMID:
18585499
5.

Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study.

Gaggin HK, Truong QA, Rehman SU, Mohammed AA, Bhardwaj A, Parks KA, Sullivan DA, Chen-Tournoux A, Moore SA, Richards AM, Troughton RW, Lainchbury JG, Weiner RB, Baggish AL, Semigran MJ, Januzzi JL Jr.

Congest Heart Fail. 2013 May-Jun;19(3):135-42. doi: 10.1111/chf.12016. Epub 2012 Dec 28.

6.

Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure.

Behnes M, Brueckmann M, Lang S, Weiß C, Ahmad-Nejad P, Neumaier M, Borggrefe M, Hoffmann U.

Clin Res Cardiol. 2014 Feb;103(2):107-16. doi: 10.1007/s00392-013-0626-6. Epub 2013 Oct 22.

PMID:
24146089
7.

[Comparative prognostic value of plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute destabilized heart failure].

Manzano-Fernández S, Januzzi JL, Boronat García M, Bonaque-González JC, Muñoz-Esparza C, Albaladejo-Otón MD, Pastor-Pérez FJ, Pastor P, Valdés M, Pascual-Figal DA.

Rev Esp Cardiol. 2011 May;64(5):365-72. doi: 10.1016/j.recesp.2010.10.017. Epub 2011 Mar 11. Spanish.

8.

Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.

Berger R, Shankar A, Fruhwald F, Fahrleitner-Pammer A, Freemantle N, Tavazzi L, Cleland JG, Pacher R.

Eur Heart J. 2009 Sep;30(17):2109-16. doi: 10.1093/eurheartj/ehp210. Epub 2009 Jun 2.

PMID:
19493864
9.

Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E.

Am J Cardiol. 2008 Sep 15;102(6):733-7. doi: 10.1016/j.amjcard.2008.04.048. Epub 2008 Jul 9.

PMID:
18773998
10.

Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy.

Magne J, Dubois M, Champagne J, Dumesnil JG, Pibarot P, Philippon F, O'Hara G, Sénéchal M.

Cardiovasc Ultrasound. 2009 Aug 20;7:39. doi: 10.1186/1476-7120-7-39.

11.

Exercise capacity and N-terminal pro-brain natriuretic peptide levels with biventricular vs. right ventricular pacing for atrioventricular block: results from the PREVENT-HF German Substudy.

Stockburger M, de Teresa E, Lamas G, Desaga M, Koenig C, Habedank D, Cobo E, Navarro X, Wiegand U.

Europace. 2014 Jan;16(1):63-70. doi: 10.1093/europace/eut217. Epub 2013 Jul 16.

PMID:
23861381
12.

The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.

Shelton RJ, Clark AL, Goode K, Rigby AS, Cleland JG.

Eur Heart J. 2006 Oct;27(19):2353-61. Epub 2006 Sep 4.

PMID:
16952921
13.

Use of N-terminal pro-brain natriuretic peptide to detect cardiac origin in critically ill cancer patients with acute respiratory failure.

Lefebvre A, Kural-Menasché S, Darmon M, Thiéry G, Feugeas JP, Schlemmer B, Azoulay E.

Intensive Care Med. 2008 May;34(5):833-9. doi: 10.1007/s00134-008-1000-4. Epub 2008 Jan 24.

PMID:
18214439
14.

Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure.

Michtalik HJ, Yeh HC, Campbell CY, Haq N, Park H, Clarke W, Brotman DJ.

Am J Cardiol. 2011 Apr 15;107(8):1191-5. doi: 10.1016/j.amjcard.2010.12.018. Epub 2011 Feb 4.

PMID:
21296322
15.

Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease.

Tung RH, Camargo CA Jr, Krauser D, Anwaruddin S, Baggish A, Chen A, Januzzi JL Jr.

Ann Emerg Med. 2006 Jul;48(1):66-74. Epub 2006 Feb 17.

PMID:
16781921
16.

Increased N-terminal-pro-B-type natriuretic peptide levels in patients with appropriate implantable defibrillator therapies.

Arnaldo FJ, Anatoliotakis N, Palacio C, Nabert DR, Hsu SS.

Heart Lung. 2009 Jan-Feb;38(1):10-6. doi: 10.1016/j.hrtlng.2007.12.005. Epub 2008 Sep 11.

PMID:
19150526
17.

Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.

Brito D, Matias JS, Sargento L, Cabral MJ, Madeira HC.

Rev Port Cardiol. 2004 Dec;23(12):1557-82. English, Portuguese.

PMID:
15732658
18.

Use of N-terminal pro-brain natriuretic peptide to detect acute cardiac dysfunction during weaning failure in difficult-to-wean patients with chronic obstructive pulmonary disease.

Grasso S, Leone A, De Michele M, Anaclerio R, Cafarelli A, Ancona G, Stripoli T, Bruno F, Pugliese P, Dambrosio M, Dalfino L, Di Serio F, Fiore T.

Crit Care Med. 2007 Jan;35(1):96-105.

PMID:
17095948
19.

Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome.

Kubler P, Jankowska EA, Majda J, Reczuch K, Banasiak W, Ponikowski P.

Int J Cardiol. 2008 Oct 13;129(3):373-8. Epub 2007 Dec 4.

PMID:
18054808
20.

N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluationof the Evolution of New-Heart Failure Study (SCREEN-HF).

McGrady M, Reid CM, Shiel L, Wolfe R, Boffa U, Liew D, Campbell DJ, Prior D, Krum H.

Eur J Heart Fail. 2013 May;15(5):573-80. doi: 10.1093/eurjhf/hft001. Epub 2013 Jan 20.

Supplemental Content

Support Center